Jaguar Animal Health (NASDAQ:JAGX) Stock Passes Below 200 Day Moving Average – Here’s Why

Jaguar Animal Health, Inc. (NASDAQ:JAGX)’s stock price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $10.01 and traded as low as $0.74. Jaguar Animal Health shares last traded at $0.7831, with a volume of 106,610 shares changing hands.

Wall Street Analyst Weigh In

JAGX has been the subject of several recent analyst reports. Wall Street Zen upgraded Jaguar Animal Health from a “sell” rating to a “hold” rating in a research note on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Jaguar Animal Health Price Performance

The business’s 50-day moving average price is $1.90 and its two-hundred day moving average price is $9.95. The firm has a market cap of $552,348.00, a price-to-earnings ratio of -0.00 and a beta of -0.06.

Jaguar Animal Health (NASDAQ:JAGX) last posted its quarterly earnings results on Wednesday, May 20th. The biotechnology company reported ($13.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($149.10) by $135.50. The company had revenue of $20.27 million during the quarter, compared to analyst estimates of $4.21 million.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.